Deals in Depth: June/July 2008
June/July 2008 dealmaking highlights: GSK is banking on insomnia with a $560mm pre-commercial value deal for Actelion's Phase III almorexant; Teva expands its hold on worldwide generics through the $8.7bn purchase of Barr; tying PIPEs for the second-most highest biopharma financing type was the Other category, consisting of TPG-Axon's $300mm investment in Lilly to support AD trials; and late VC money dominates medical device financing, accounting for 45% of the $744mm total.
You may also be interested in...
Gene therapy remains attractive when data show new technologies can advance the field, but gene regulation, editing and RNA therapies are grabbing investors’ attention, panelists said at ARM’s Cell and Gene Meeting on the Mesa.
Gilead looks set to expand its lead position in the triple-negative breast cancer (TNBC) market in Europe with a positive opinion for Trodelvy from the CHMP.
Company seeks to avoid Medicaid “best price” implications by administering the program through an insurance policy with AIG, which is handling claims for refunds and processing payments.